Literature DB >> 8036157

Formation of adriamycin--DNA adducts in vitro.

C Cullinane1, S M Cutts, A van Rosmalen, D R Phillips.   

Abstract

Adriamycin is known to induce the formation of adducts with DNA when reacted under in vitro transcription conditions. The factors affecting the extent of adduct formation were examined in order to establish the critical components and optimal conditions required for the reaction, and to gain insight into the nature of the DNA-adduct complex. There was a strong dependence on reaction temperature (with a 40-fold increase of adducts at 40-50 degrees C compared to 10 degrees C), pH (maximum adducts at pH 7), but little dependence on the oxygen level. There was an absolute requirement for a reducing agent, with adducts detected with DTT, beta-mercaptoethanol and glutathione, maximal adducts were formed at high levels of DTT (5-10 mM). Adducts were also formed with a xanthine oxidase/NADH reducing system, with increasing amounts of adducts detected with increasing NADH; no adducts were detected in the absence of either the enzyme or NADH. Of fourteen derivatives studied, only four yielded a similar extent of adduct formation as adriamycin; there was no absolute requirement for a carbonyl at C13 or hydroxyl at C14. Adducts were also observed with ssDNA but required a longer reaction time compared to dsDNA. The sequence specificity of adduct formation with ssDNA was examined using a primer-extension assay; almost all adducts were associated with a guanine residue. Overall, the results are consistent with a two-step reaction mechanism involving reductive activation of adriamycin, with the activated species then reacting with the guanine residues of either dsDNA or ssDNA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8036157      PMCID: PMC523687          DOI: 10.1093/nar/22.12.2296

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  35 in total

Review 1.  Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling.

Authors:  H Kappus
Journal:  Biochem Pharmacol       Date:  1986-01-01       Impact factor: 5.858

2.  Binding of transferrin-iron by adriamycin at acidic pH.

Authors:  E J Demant; N Nørskov-Lauritsen
Journal:  FEBS Lett       Date:  1986-02-17       Impact factor: 4.124

3.  Binding of [14C]-adriamycin to cellular macromolecules in vivo.

Authors:  B K Sinha; R H Sik
Journal:  Biochem Pharmacol       Date:  1980-06-15       Impact factor: 5.858

4.  One-electron reduction of adriamycin: properties of the semiquinone.

Authors:  E J Land; T Mukherjee; A J Swallow; J M Bruce
Journal:  Arch Biochem Biophys       Date:  1983-08       Impact factor: 4.013

5.  Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex.

Authors:  C E Myers; L Gianni; C B Simone; R Klecker; R Greene
Journal:  Biochemistry       Date:  1982-04-13       Impact factor: 3.162

6.  Solution chemistry studies of adriamycin--iron complexes present in vivo.

Authors:  P M May; G K Williams; D R Williams
Journal:  Eur J Cancer       Date:  1980-09       Impact factor: 9.162

7.  Enzymatic activation and binding of adriamycin to nuclear DNA.

Authors:  B K Sinha; M A Trush; K A Kennedy; E G Mimnaugh
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

8.  Reactions of Adriamycin with haemoglobin. Superoxide dismutase indirectly inhibits reactions of the Adriamycin semiquinone.

Authors:  D A Bates; C C Winterbourn
Journal:  Biochem J       Date:  1982-04-01       Impact factor: 3.857

9.  Anthracycline antibiotic reduction by spinach ferredoxin-NADP+ reductase and ferredoxin.

Authors:  J Fisher; B R Abdella; K E McLane
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

10.  Methidiumpropyl-EDTA.Fe(II) and DNase I footprinting report different small molecule binding site sizes on DNA.

Authors:  M W Van Dyke; P B Dervan
Journal:  Nucleic Acids Res       Date:  1983-08-25       Impact factor: 16.971

View more
  10 in total

1.  Adriamycin-Induced Models of VACTERL Association.

Authors:  D Mc Laughlin; P Hajduk; P Murphy; P Puri
Journal:  Mol Syndromol       Date:  2013-02

2.  Stability of adriamycin-induced DNA adducts and interstrand crosslinks.

Authors:  A van Rosmalen; C Cullinane; S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

Review 3.  The Adriamycin rat/mouse model and its importance to the paediatric surgeon.

Authors:  J Gillick; A Mortell; M Dawrant; S Giles; J Bannigan; P Puri
Journal:  Pediatr Surg Int       Date:  2008-01       Impact factor: 1.827

4.  Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.

Authors:  Brian T Kalet; Meagan B McBryde; Joaquin M Espinosa; Tad H Koch
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

5.  A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues.

Authors:  Andrew T Lucas; Sara K O'Neal; Charlene M Santos; Taylor F White; William C Zamboni
Journal:  J Pharm Biomed Anal       Date:  2015-11-28       Impact factor: 3.935

6.  Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin.

Authors:  S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-07-11       Impact factor: 16.971

7.  The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.

Authors:  D Kostrzewa-Nowak; M J I Paine; C R Wolf; J Tarasiuk
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

8.  Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.

Authors:  Kate E Coldwell; Suzanne M Cutts; Ted J Ognibene; Paul T Henderson; Don R Phillips
Journal:  Nucleic Acids Res       Date:  2008-07-16       Impact factor: 16.971

9.  Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients.

Authors:  Kristine Walters; Alessia Stornetta; Foster Jacobs; Peter W Villalta; Maria Razzoli; Marianne Grant; Beshay Zordoky; Alessandro Bartolomucci; Antonella Borgatti; Silvia Balbo
Journal:  BMC Vet Res       Date:  2021-12-07       Impact factor: 2.741

10.  Importance of intracellular pH in determining the uptake and efficacy of the weakly basic chemotherapeutic drug, doxorubicin.

Authors:  Pawel Swietach; Alzbeta Hulikova; Shalini Patiar; Richard D Vaughan-Jones; Adrian L Harris
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.